Search articles in Pharma News

Found 466 articles

  • Immutep Announces GMP Manufacturing Process Develo

    Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

    • 7 Dec 2022
    • Editor

    Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has been established for IMP761, its proprietary preclinical candidate for autoimmune diseases. The 200L scale attained by Northway Biotech will ensure supply of IMP761 for IND-enabling studies and ensuing clinical trials.

  • HUMAN celebrates its 50th anniversary

    HUMAN celebrates its 50th anniversary

    • 6 Dec 2022
    • Editor

    Since its foundation in 1972, HUMAN Gesellschaft für Biochemica und Diagnostica mbH has been developing and marketing comprehensive solutions for in vitro diagnostics (IVD). The portfolio ranges from classical clinical chemistry to innovative molecular diagnostic methods as well as special applications such as assays for autoimmunity testing.

  • PharmiWeb.Jobs Announces New Partnership With PCMG

    PharmiWeb.Jobs Announces New Partnership With PCMG

    • 5 Dec 2022
    • Editor

    PharmiWeb.Jobs, Europe’s largest dedicated Life Science job board, is pleased to announce its new partnership with the Pharmaceutical Contract Management Group (PCMG), a unique association of Outsourcing and Procurement professionals working in Research and Development functions across the pharmaceutical industry.

  • Kuros Biosciences Completes Enrollment of Randomiz

    Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH

    • 23 Nov 2022
    • Editor

    Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the completion of enrollment in the randomized stage of the STRUCTURE trial, which is investigating the safety and efficacy of Fibrin-PTH (KUR-113) in transforaminal lumbar interbody fusion (TLIF) procedures in patients with degenerative disc disease (DDD).

  • Medios AG: Acquisition of Blisterzentrum Baden-Wür

    Medios AG: Acquisition of Blisterzentrum Baden-Württemberg GmbH and expansions in the area of sterile manufacturing

    • 22 Nov 2022
    • Editor

    Medios AG ("Medios") today entered into a purchase agreement for the acquisition of Blisterzentrum Baden-Württemberg GmbH ("bbw") and agreed on a cooperation in the field of sterile manufacturing with Apotheken für Spezialversorgungen OHG ("AfS").

  • ANGELINI INDUSTRIES APPOINTS JACOPO ANDREOSE  NEW

    ANGELINI INDUSTRIES APPOINTS JACOPO ANDREOSE NEW CEO OF ANGELINI PHARMA

    • 22 Nov 2022
    • Editor

    Angelini Industries announces the appointment of Jacopo Andreose as new Chief Executive Officer of Angelini Pharma, a pharmaceutical company active in brain health, including mental health and epilepsy, and consumer healthcare, which is part of the Angelini Industries, an Italian multi-business group.

  • Weekly Pharma & Life Science News Round-Up: 14th –

    Weekly Pharma & Life Science News Round-Up: 14th – 18th November

    • 18 Nov 2022
    • Lucy Walters

    A round-up of the latest news from the Pharma & Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 14th-18th November.

  • REGENERON AND CYTOMX ANNOUNCE STRATEGIC RESEARCH C

    REGENERON AND CYTOMX ANNOUNCE STRATEGIC RESEARCH COLLABORATION IN THE FIELD OF CONDITIONAL BISPECIFIC THERAPEUTICS FOR THE TREATMENT OF CANCER

    • 18 Nov 2022
    • Editor

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and CytomX Therapeutics, Inc. (NASDAQ: CTMX) today announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX's Probody® therapeutic platform and Regeneron's Veloci-Bi® bispecific antibody development platform.

  • PAION AG enters partnership with Viatris and expan

    PAION AG enters partnership with Viatris and expands sales activities in Europe

    • 16 Nov 2022
    • Editor

    PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and hospital sedation, anaesthesia and intensive care, has entered into a long-term collaboration with Mylan Ireland Limited, a subsidiary of the Viatris Group, for the distribution in both Southern Europe and other European countries which are not currently served by PAION or its other distribution partner Medis.

  • Weekly Pharma & Life Science News Round-Up: 7th No

    Weekly Pharma & Life Science News Round-Up: 7th November – 11th November

    • 11 Nov 2022
    • Editor

    A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 7th-11th November.

  • EVERSANA® Named Great Place to Work Across Five Co

    EVERSANA® Named Great Place to Work Across Five Countries on Three Continents

    • 8 Nov 2022
    • Editor

    EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry, once again has been recognized globally as a Great Place to Work® by the leading authority in workplace culture. Based on an anonymous survey of more than 6,000 EVERSANA employees worldwide, the company earned recognition for the fourth consecutive year in the United States, the second straight year in Canada and India, and for the first time in both the United Kingdom and Singapore.

  • Weekly Pharma & Life Science News Round-Up: 31st O

    Weekly Pharma & Life Science News Round-Up: 31st October – 4th November

    • 4 Nov 2022
    • Lucy Walters

    A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 31st October – 4th November.

  • Aptar Again Named a Global Top Female-Friendly Com

    Aptar Again Named a Global Top Female-Friendly Company by Forbes

    • 3 Nov 2022
    • Editor

    AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, today announced it has again been named one of the World’s Top Female-Friendly Companies by Forbes.

  • Top Pharmaceutical and Life Science Events in Nove

    Top Pharmaceutical and Life Science Events in November (2022)

    • 1 Nov 2022
    • Lucy Walters

    Top Pharmaceutical and Life Science events taking place in November 2022, including Biotechnology, Clinical Research, Drug Discovery and Medical Device events.

  • Obsidian Therapeutics Announces Extension of Multi

    Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb

    • 27 Oct 2022
    • Editor

    Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that Bristol Myers Squibb (NYSE:BMY) has opted to extend the term of the parties’ multi-year strategic collaboration for the discovery and development of novel, regulated cell therapies that utilize Obsidian’s cytoDRiVE® technology for the controlled expression of the immune enhancer CD40L.

  • Applications open for SmiLe e-Campus – an introduc

    Applications open for SmiLe e-Campus – an introduction program to life science entrepreneurship

    • 27 Oct 2022
    • Editor

    SmiLe e-Campus is a free, online training program for future life science entrepreneurs, organized in collaboration with GE Healthcare and Philips. The program is open for graduates, researchers, and early-stage entrepreneurs from all over Europe and has received excellent reviews from participants of previous rounds.

  • Radiopharm Theranostics signs agreement with North

    Radiopharm Theranostics signs agreement with NorthStar Medical Radioisotopes for the supply of non-carrier added (n.c.a.) Actinium-225

    • 27 Oct 2022
    • Editor

    Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced they have entered into a clinical supply agreement that will see NorthStar supply Radiopharm with Actinium-225.

  • Dante Genomics creates separate drug discovery and

    Dante Genomics creates separate drug discovery and development company Genomic Biopharma Inc.

    • 26 Oct 2022
    • Editor

    Dante Genomics, a global leader in genomics and precision medicine, today announced the creation of Genomic Biopharma Inc., a separate drug discovery and development company to distinguish the separate business streams of each entity.

  • Myelodysplastic Syndromes (MDS) World Awareness Da

    Myelodysplastic Syndromes (MDS) World Awareness Day

    • 25 Oct 2022
    • Editor

    Also known as a form of blood cancer, Myelodysplastic syndromes (MDS) are an often unrecognised, under-diagnosed rare group of bone marrow failure disorders, where the body no longer makes enough healthy, normal blood cells in the bone marrow.

  • Syncona to acquire Applied Genetic Technologies Co

    Syncona to acquire Applied Genetic Technologies Corporation (AGTC)

    • 24 Oct 2022
    • Editor

    Syncona Limited, a leading healthcare company focused on founding, building and funding global leaders in life science, today announces that its newly established portfolio company has agreed to acquire, by a tender offer, all outstanding shares of Applied Genetic Technologies Corporation ("AGTC") (Nasdaq: AGTC).